Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

被引：0
|
作者：
Mats Någård
Mei-Lin Ah-See
Karen So
Marit Vermunt
Fiona Thistlethwaite
Mariette Labots
Patricia Roxburgh
Alain Ravaud
Mario Campone
Liselot Valkenburg-van Iersel
Lone Ottesen
Yan Li
Ganesh Mugundu
机构：
[1] R&D Clinical Pharmacology and Safety Sciences,Clinical Pharmacology and Quantitative Pharmacology
[2] AstraZeneca,Late Stage Development, Oncology R&D
[3] AstraZeneca,Clinical Pharmacology Biologics and Bioanalysis, Clinical Pharmacology and Safety Science, BioPharmaceuticals R&D
[4] The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital,Clinical Pharmacology and Quantitative Pharmacology, R&D Clinical Pharmacology and Safety Sciences
[5] The Christie NHS Foundation Trust and University of Manchester,undefined
[6] Cancer Center Amsterdam,undefined
[7] Amsterdam UMC,undefined
[8] Beaston West of Scotland Cancer Centre and University of Glasgow,undefined
[9] Bordeaux University Hospital,undefined
[10] ICO – Site René,undefined
[11] Maastricht University Medical Centre,undefined
[12] AstraZeneca,undefined
[13] AstraZeneca,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
Adavosertib; Food effect; Pharmacokinetics; Oncology; WEE1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：97 / 108
页数：11
相关论文
共 50 条
  • [21] Sequential treatment with the Wee1 inhibitor, AZD1775, enhances the effect of trabectedin in the L-sarcomas
    Musi, Elgilda
    Ambrosini, Grazia
    Schwartz, Gary K.
    CANCER RESEARCH, 2017, 77
  • [22] A phase 2 study of the WEE1 inhibitor AZD1775 in SETD2-deficient advanced solid tumor malignancies.
    Maldonado, Edward
    Rathmell, Wendy Kimryn
    Shapiro, Geoffrey
    Ahnert, Jordi Rodon
    Mahalingam, Devalingam
    Trikalinos, Nikolaos
    Rezazadeh, Arash
    Febles, Victor Ricardo Adorno
    Parikh, Mamta
    Boerner, Scott Anthony
    Krings, Gregor
    Takebe, Naoko
    LoRusso, Patricia
    Aggarwal, Rahul Raj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] MODEL BASED ANALYSIS OF THE EFFECT OF AZD1775, A WEE1 KINASE INHIBITOR ON OLAPARIB EXPOSURE.
    Johnson, M.
    Schmidt, H.
    Ottesen, L.
    Mugundu, G.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S107 - S107
  • [24] Phase I/II Study of the WEE1 Inhibitor Adavosertib (AZD1775) in Combination with Carboplatin in Children with Advanced Malignancies: Arm C of the AcSé-ESMART Trial
    Gatz, Susanne A.
    Harttrampf, Anne C.
    Brard, Caroline
    Bautista, Francisco
    Andre, Nicolas
    Abbou, Samuel
    Rubino, Jonathan
    Rondof, Windy
    Deloger, Marc
    Rubsam, Marc
    Marshall, Lynley V.
    Hubschmann, Daniel
    Nebchi, Souad
    Aerts, Isabelle
    Thebaud, Estelle
    De Carli, Emilie
    Defachelles, Anne Sophie
    Paoletti, Xavier
    Godin, Robert
    Miah, Kowser
    Mortimer, Peter G. S.
    Vassal, Gilles
    Geoerger, Birgit
    CLINICAL CANCER RESEARCH, 2024, 30 (04) : 741 - 753
  • [25] Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).
    Naqash, Abdul Rafeh
    Mittra, Arjun
    Coyne, Geraldine Helen O'Sullivan
    Chen, Li
    Das, Biswajit
    Kummar, Shivaani
    Do, Khanh T.
    Chang, Ting-Chia
    Bruns, Ashley
    Juwara, Lamin
    Miller, Brandon
    Kinders, Robert J.
    Parchment, Ralph E.
    Rubinstein, Larry, V
    Ji, Jiuping Jay
    Wilsker, Deborah
    Dull, Angie B.
    Doroshow, James H.
    Chen, Alice P.
    Takebe, Naoko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] A dose escalation trial of the Wee1 inhibitor AZD1775, in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer
    Cuneo, Kyle C.
    Morgan, Meredith A.
    Zalupski, Mark M.
    Sahai, Vaibhav
    Schipper, Matthew J.
    Maybaum, Jonathan
    Lawrence, Theodore S.
    CANCER RESEARCH, 2019, 79 (13)
  • [27] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
    Falchook, Gerald S.
    Sachdev, Jasgit
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Jenkins, Suzanne
    Chmielecki, Juliann
    Jones, Suzanne
    Spigel, David R.
    Johnson, Melissa
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 493 - 502
  • [28] A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
    Gerald S Falchook
    Jasgit Sachdev
    Esteban Rodrigo Imedio
    Sanjeev Kumar
    Ganesh M Mugundu
    Suzanne Jenkins
    Juliann Chmielecki
    Suzanne Jones
    David R Spigel
    Melissa Johnson
    Investigational New Drugs, 2023, 41 : 493 - 502
  • [29] A dose escalation trial of the WEE1 inhibitor AZD1775, gemcitabine, and concurrent radiation in locally advanced pancreatic cancer
    Cuneo, Kyle C.
    Morgan, Meredith
    Schipper, Matthew J.
    Maybaum, Jonathan
    Feng, Mary U.
    Al-Hawary, Mahmoud
    Simeone, Diane M.
    Olson, Leah D.
    Sahai, Vaibhav
    Zalupski, Mark
    Lawrence, Theodore S.
    CANCER RESEARCH, 2016, 76
  • [30] Pediatric phase 2 trial of the WEE1 inhibitor adavosertib (AZD1775) and irinotecan: A Children's Oncology Group Study (ADVL1312).
    Cole, Kristina A.
    Ijaz, Heba
    Surrey, Lea
    Santi-Vicini, Mariarita
    Liu, Xiaowei
    Minard, Charles G.
    Maris, John M.
    Voss, Stephan
    Fox, Elizabeth
    Weigal, Brenda
    CANCER RESEARCH, 2021, 81 (13)
12345